Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry

Bruce Keyt Sells 10,000 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) Stock

Defense World ·  {{timeTz}}

IGM Biosciences, Inc. (NASDAQ:IGMS – Get Rating) insider Bruce Keyt sold 10,000 shares of IGM Biosciences stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $19.78, for a total transaction of $197,800.00. Following the sale, the insider now owns 39,489 shares of the company's stock, valued at $781,092.42. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Bruce Keyt also recently made the following trade(s):

Get IGM Biosciences alerts:
  • On Tuesday, September 6th, Bruce Keyt sold 5,000 shares of IGM Biosciences stock. The shares were sold at an average price of $19.06, for a total transaction of $95,300.00.
  • On Friday, August 19th, Bruce Keyt sold 8,700 shares of IGM Biosciences stock. The shares were sold at an average price of $22.82, for a total transaction of $198,534.00.
  • On Monday, August 22nd, Bruce Keyt sold 6,300 shares of IGM Biosciences stock. The stock was sold at an average price of $20.71, for a total transaction of $130,473.00.

IGM Biosciences Stock Performance

IGMS stock opened at $21.25 on Friday. The stock has a market capitalization of $903.76 million, a P/E ratio of -3.74 and a beta of -0.32. IGM Biosciences, Inc. has a one year low of $12.67 and a one year high of $76.20. The company has a 50 day moving average price of $20.04 and a two-hundred day moving average price of $18.47.

IGM Biosciences (NASDAQ:IGMS – Get Rating) last posted its earnings results on Monday, August 8th. The company reported ($1.33) earnings per share for the quarter, beating the consensus estimate of ($1.44) by $0.11. The business had revenue of $0.37 million for the quarter, compared to analyst estimates of $38.91 million. During the same quarter in the previous year, the firm posted ($1.16) EPS. Research analysts forecast that IGM Biosciences, Inc. will post -5.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On IGM Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Point72 Hong Kong Ltd acquired a new position in shares of IGM Biosciences during the 4th quarter valued at $34,000. Amalgamated Bank acquired a new position in IGM Biosciences in the 1st quarter worth $36,000. US Bancorp DE lifted its holdings in IGM Biosciences by 608.4% in the 1st quarter. US Bancorp DE now owns 2,437 shares of the company's stock worth $65,000 after buying an additional 2,093 shares in the last quarter. Captrust Financial Advisors acquired a new position in IGM Biosciences in the 2nd quarter worth $50,000. Finally, American International Group Inc. lifted its holdings in IGM Biosciences by 15.0% in the 2nd quarter. American International Group Inc. now owns 4,684 shares of the company's stock worth $84,000 after buying an additional 612 shares in the last quarter. Institutional investors and hedge funds own 41.20% of the company's stock.

Wall Street Analysts Forecast Growth

IGMS has been the subject of a number of recent research reports. Guggenheim dropped their price objective on shares of IGM Biosciences to $40.00 in a research note on Monday, August 15th. Bank of America initiated coverage on shares of IGM Biosciences in a research note on Monday, August 29th. They set a "buy" rating and a $34.00 price objective for the company. HC Wainwright dropped their price objective on shares of IGM Biosciences from $59.00 to $58.00 and set a "buy" rating for the company in a research note on Tuesday, May 17th. Truist Financial dropped their price objective on shares of IGM Biosciences from $74.00 to $37.00 and set a "buy" rating for the company in a research note on Tuesday, August 23rd. Finally, Robert W. Baird lowered their target price on shares of IGM Biosciences from $46.00 to $31.00 and set an "outperform" rating for the company in a research note on Wednesday, June 1st. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $53.00.

IGM Biosciences Company Profile

(Get Rating)

IGM Biosciences, Inc, a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL).

Featured Stories

  • Get a free copy of the StockNews.com research report on IGM Biosciences (IGMS)
  • MarketBeat: Week in Review 9/5 – 9/9
  • Prepare For A Record-Setting Quarter For Cyber Security Stocks
  • The Auto Market Is Slowly Recovering, These Stocks May Outperform
  • Is DocuSign On The Verge Of A Major Reversal?
  • Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy

Receive News & Ratings for IGM Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGM Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.